|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Adenosine concentration and TNF-alpha levels were increased in plasma of patients with PD.
|
19776336 |
2010 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Logistic binary regression analysis showed that the genetic background leading to higher TNF-α expression confers a higher risk to develop PD earlier.
|
28844731 |
2017 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
There are conflicting studies to serum level of TNF-α in PD.
|
29408778 |
2018 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Although there was a tendency for hypomethylation in PD, our analysis of the 10 CpGs in the TNF-alpha core promoter region (-258 to -35 relative to the TSS) revealed no particular pattern in PD patients compared to control and identified no particular hypomethylated position in cortex or SNpc DNA.
|
18930140 |
2008 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To study the association between Parkinson's disease (PD)-related pain and plasma interleukin (IL)‑1, IL‑6, IL‑10, and tumour necrosis factor (TNF)‑α levels.
|
30063943 |
2018 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Peripheral cytokines profile in Parkinson's disease.
|
18678243 |
2009 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Increased GLRX copy number in PD patients was associated with earlier PD onset; and Grx1 levels correlated with levels of proinflammatory tumor necrosis factor-α in mouse and human brain samples.
|
29183158 |
2019 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To test the hypothesis whether the methylation state of the TNF-alpha promoter contributes to increased expression of TNF-alpha in PD we compared DNA from different brain regions (substantia nigra pars compacta (SNpc) and cortex) of PD patients and neurologically healthy, age and sex matched controls by bisulfite sequencing of the TNF-alpha promoter region.
|
18930140 |
2008 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Human neuroblastoma cell line SH-SY5Y was treated with 1-Methyl-4-phenylpyridinium (MPP<sup>+</sup>) to mimic PD model in vitro. qRT-PCR was employed to detect the expression of NEAT1, IL-1β, IL-6 and TNF-α.
|
31228597 |
2019 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells.
|
10212304 |
1999 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Pretreatment with CUMS for 14 days increased the levels of interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-a (TNF-a) in the serum, and increased the expression of NLRP-3, ASC, Casepase-1 in the substantia nigra of PD rats.
|
30658122 |
2019 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Programmed cell death of the nigro-striatal dopamine neurons in PD has been suggested from the following findings on postmortem brains: (1) increased levels of pro-inflammatory cytokines such as TNF-alpha and IL-6; (2) increased levels of apoptosis-related factors such as TNF-alpha receptor R1 (p 55), soluble Fas and bcl-2, and increased activities of caspases 1 and 3; and (3) decreased levels of neurotrophins such as brain-derived nerve growth factor (BDNF).
|
17982884 |
2007 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Malondialdehyde and tumor necrosis factor alpha levels increased in the rats with PD induced by rotenone, whereas malondialdehyde and tumor necrosis factor alpha levels markedly decreased in the rats treated with exenatide.
|
28918840 |
2017 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elevated expression of TNF-α is associated with numerous neurodegenerative diseases including Alzheimer's Disease and Parkinson's Disease.
|
31443122 |
2019 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Plasma concentrations of IL-1β, IL-2, IL-4, IL-6, IL-13, IL-18, GM-CSF, IFNγ, and TNFα were measured by a multiplex immunoassay and relationships between microbiota, clinical characteristics, and cytokine levels were analyzed in the PD group.
|
31248424 |
2019 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
After the 12-week intervention, compared with the placebo, omega-3 fatty acids and vitamin E co-supplementation downregulated gene expression of tumor necrosis factor alpha (TNF-α) (P = 0.002) in PBMC of subjects with PD.
|
30554092 |
2019 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
For the first time, the multilocus approach by the set-association method has been applied for the analysis of a cluster of five genes [tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), IL-8, IL-1alpha and IL-10] involved in the brain neuroinflammatory pathway in Parkinson's disease (PD), in a well-defined group of 197 PD patients and 173 control subjects from Spain.
|
18284424 |
2008 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease.
|
21472005 |
2011 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
CTD_human |
Table 1 Biochemical Alterations in Substantia Nigra of Parkinson's Disease Indicating Oxidative Stress Elevated Decreased Iron (in microglia, astrocytes, oligodendrocytes, and melanized dopamine neurons and mitochondria) GSH (GSSG unchanged); GSH/GSSG ratio decreased Mitochondrial complex I Ferritin Calcium binding protein (calbindin 28) Mitochondrial monoamine oxidase B Transferrin and transferrin receptor Lipofuscin Vitamins E and C Ubiquitin Copper Cu/Zn-superoxide dismutase Cytotoxic cytokines (TNF-a, IL-1, IL-6) Inflammatory transcription factor NFKB Heme oxygenase-1 Ratio of oxidized to reduced glutathione (GSSG/GSH) Nitric oxide Neuromelanin.
|
21318773 |
2001 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
TNF-α, which is highly toxic to dopaminergic neurons, is implicated as a major mediator of neuroinflammation in PD.
|
30515090 |
2018 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
No positive correlation between 3-HK and TNF-α was seen in PD.
|
31654722 |
2020 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We recently demonstrated that the TNFalpha pathway contributes to the pathogenesis of sporadic PD using a genetic approach.
|
12203044 |
2002 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since depression is a common co-morbid condition with PD, we undertook this study to determine whether Hc-TeTx might also show antidepressant-like properties and whether central brain-derived neurotrophic factor (BDNF) and/or tumor necrosis factor (TNF)-alpha are also affected by it.
|
31125623 |
2019 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Finally, linear discriminant analysis revealed that serum TNF and CSF α-synuclein discriminated between PD and HC with a minimum of 82% sensitivity and 83% specificity.
|
28821274 |
2017 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These promising findings provide compelling reasons to perform DN-TNF gene transfer studies in nonhuman primates with the long-term goal of using it in the clinic to prevent the delayed and progressive degeneration of DA neurons that gives rise to motor symptoms in PD.
|
20959812 |
2011 |